Skip to main content


Notice of Revision of Licensing Fee Equivalent for the Distribution of Bioresources Covered by Patents Owned by Takara Bio USA, Inc.

RIKEN BioResource Research Center (BRC) and Takara Bio USA, Inc. (TBUSA) have entered into a licensing agreement regarding the preservation and distribution of bioresources containing fluorescent proteins covered by patents owned by TBUSA, initially in January 2016 and subsequently in April 2018. According to the agreement, in distribution of the relevant fluorescent proteins, users are required to bear a licensing fee equivalent amount.

In January 2024, due to changes in the licensing fees resulting from the revision of the licensing agreement with TBUSA, as well as a reassessment prompted by recent exchange rate fluctuations, BRC has decided to revise the licensing fee equivalent amount as follows. We kindly ask for your understanding in this matter.

BRC will continue to strive towards enhancing the availability and quality of bioresources, aiming to contribute to the advancement of research activities for all users. We look forward to your continued active utilization.

Best Regards,
Director, Toshihiko Shiroishi, Ph.D.
RIKEN BioResource Research Center

Effective Fee Revision Date:

For bioresources requested after April 1, 2024 (Monday) Japan Time, BRC will distribute them at the revised fees. For requests made before this date, the current fees will apply.

Amount of Licensing Fee Equivalent:

Contact offices:

For further details, please contact the respective Divisions: